About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT00899015

Assessing Arsenic Trioxide in Young Patients With Leukemia or Lymphoma Who Were Treated on Clinical Trial NCI-00-C-0070J

RATIONALE: Studying bone marrow and blood samples from patients with leukemia or lymphoma treated with arsenic trioxide may help doctors learn more about cancer. PURPOSE: This research study is asses...

Lead sponsor: National Institutes of Health Clinical Center (CC)•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

National Institutes of Health Clinical Center (CC)

Collaborators

National Cancer Institute (NCI)

OBJECTIVES: * To assess the pharmacokinetic and pharmacodynamic profiles of arsenic trioxide in pediatric patients treated on protocol NCI-00-C-0070J. OUTLINE: Bone marrow or peripheral blood mononuclear cells collected during treatment on NCI-00-C-0070J are assessed for pharmacodynamics studies. Plasma cells collected during treatment are assessed for pharmacokinetics studies. Total arsenic (As), inorganic As forms (AsIII and AsV), and methylated metabolites of As are assessed.

Age

2 - 21 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•DISEASE CHARACTERISTICS:
•Histologically confirmed leukemia or lymphoma refractory to standard curative treatment regimens
•* No meningeal leukemia or lymphoma
•* No HIV-related lymphoma
•* No lymphoproliferative diseases
•Received treatment on protocol NCI-00-C-0070J
•Bone marrow or peripheral blood and serum samples collected during treatment on NCI-00-C-0070J are available
•PATIENT CHARACTERISTICS:
•See NCI-00-C-0070J
•PRIOR CONCURRENT THERAPY:
•See NCI-00-C-0070J

Related studies

RECRUITINGPhase 1

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

NCT06197672 · Acute Myeloid Leukemia

RECRUITINGPhase 2

A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia

NCT07400029 · Acute Lymphoblastic Leukemia

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

NCT02682667 · Multiple Myeloma, Lymphoma, Non-Hodgkin, and more

RECRUITINGPhase 1

Phase I Study of HC-7366 for Acute Myeloid Leukemia

NCT06285890 · Acute Myeloid Leukemia

RECRUITINGPhase 2

Venetoclax Combined With Azacitidine for Consolidation Therapy in AML

NCT07425782 · Acute Myeloid Leukemia, Consolidation Therapy, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 16, 2012Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment23

Start date—

Last updatedMar 16, 2012

Condition

Leukemia Lymphoma

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 16, 2012Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions